Sacituzumab tirumotecan (sac-TMT) significantly improved progression-free survival compared to chemotherapy in HR-positive, ...
Data demonstrated that vepdegestrant maintained patients’ quality of life for statistically significantly longer and delayed worsening of ...
MedPage Today on MSN
Endocrine Therapy Resistance in HR+/HER2- Breast Cancer: A Common Clinical Challenge
Endocrine therapy typically slows cell cycle progression by reducing cyclin D1, which partners with CDK4/6 to promote cell ...
MedPage Today on MSN
For Your Patients: Next Steps If There Is Resistance to Endocrine Therapy
When cancer progresses on endocrine therapy, the next step is likely either a biopsy to gather tissue for testing or a liquid ...
Patients with an aggressive form of breast cancer who are not candidates for immune checkpoint inhibitor therapy showed ...
Alphamab Oncology (stock code: 9966.HK) announced that two latest clinical data on biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003 for the treatment of primary platinum-refractory ...
Gedatolisib combined with fulvestrant, with or without palbociclib, significantly improved PFS in HR-positive, HER2-negative, PIK3CA wild-type advanced breast cancer. The triplet regimen reduced ...
Triple-negative breast cancer does not respond to targeted breast cancer treatments, which limits treatment to primarily ...
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that at the 2025 European Society for Medical ...
MedPage Today on MSN
Trastuzumab Deruxtecan Scores Two Wins in HER2-Positive Early Breast Cancer
BERLIN -- The antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd, Enhertu) delivered impressive results in different ...
Learn about HER2+ breast cancer, its aggressive nature, and the latest treatments available in India. Explore the impact of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback